About this Research Topic
Prostate Cancer (PCa) is the most frequently diagnosed cancer among men in developed countries and one of the most heritable solid tumors with 58% of cases estimated to be due to genetic factors. The effectiveness of PSA screening remains controversial and new molecular biomarkers are needed to improve screening and clinical management of disease. Nowadays, many variants have been identified in the PCa genome, also differentially expressed genes have been defined but the key biological mechanisms remain unclear and we need new biomarkers to classify the genes and their regulatory elements related to its progression. With this proposal we aim to have an overlook about all the current biomarkers that are used in PCs in different focuses such as diagnosis, prognosis or follow-up. Moreover, we would like to focus on the molecular approaches that are currently studied as biomarkers in this tumor.
Our proposal aims to invite researchers with remarkable experience in PCa to submit their latest findings in novel biomarkers that can be potentially used in the diagnosis, prognosis, monitoring and surveillance of the disease. We would like to pay special attention to studies involving cutting-edge technologies for the identification and characterization of novel PCa biomarkers. We believe that this would contribute to enhance the prestige of the Frontiers in Genetics journal and to generate interest from the scientific community. Moreover, insights into the molecular mechanisms underlying PCa development could lead to the identification of novel therapeutic targets and help researchers to develop personalized therapies in PCa. Finally, since PCa shares molecular characteristics with other epithelial cancers, we believe that the publication of new biomarkers could also be relevant for other researchers and clinicians working in the detection and treatment of other malignancies.
We welcome the submission of manuscripts covering the following subtopics:
• Identification of new biomarkers with potential applications in screening and management of prostate cancer (PCa).
• Analysis of the main molecular pathways involved in early stages of PCa development.
• Study of molecular pathways associated with hormonal signaling and their implications in tumor progression.
• Unraveling the mechanisms of action of novel biomarkers involved in PCa metastasis.
• Pharmacogenomics/pharmacogenetics in PCa and identification of targetable molecules, with special focus on metastatic castration resistant PCa (mCRPC)
• Detection of biomarkers using liquid biopsies.
• Application of other cutting-edge technologies in the detection and characterization of PCa molecular biomarkers such as chromosome conformation capture assays, three-dimensional cultures and arrays.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.